Whole-body MRI (WBMRI) has been extensively investigated for its role in managing neurocutaneous syndromes, including neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and other malignancy-related conditions, due to its comprehensive imaging potential for assessing tumor burden and differentiating between various tumor types in affected patients [11]. This evidence concerns the gene NF2 and neurofibromatosis type 1.